On December 13, Gelonghui reported that Fuyuan Pharmaceutical (601089.SH) announced that on December 12, 2024, the company participated in the bidding work for the tenth batch of national centralized pharmaceutical procurement organized by the National Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"). After opening and evaluating the bids by the Joint Procurement Office, the company's product, azilsartan and hydrochlorothiazide tablets, is expected to win the bid for this centralized procurement. The selection of supply provinces for azilsartan and hydrochlorothiazide tablets has been based on market potential in each province, and the results will be officially released after being announced by the Joint Procurement Office.
福元医药(601089.SH)：参与第十批全国药品集中采购拟中选
Fuyuan Pharmaceutical (601089.SH): Participating in the tenth batch of national Pharmaceutical centralized procurement is expected to be selected.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.